|Day's range||57.95 - 58.20|
If you buy and hold a stock for many years, you'd hope to be making a profit. Better yet, you'd like to see the share...
J&J's (JNJ) cancer drugs are expected to have contributed significantly to fourth-quarter 2019 earnings. Generic/biosimilar headwinds are expected to have hurt Pharma unit's sales.
With most blue-chip companies' earnings scheduled over the coming weeks and sentiments being mixed, investors should closely monitor the movement of the Dow ETF.
Wall Street rallied following the first phase of the U.S.-China trade pact, with Dow Jones Industrial Average and S&P 500 closing at record highs.
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
Yahoo Finance Editor-in-Chief Andy Serwer sits down with Chairman of the Children’s Health Defense, and President of the Waterkeeper Alliance, Robert F. Kennedy, Jr.
Johnson & Johnson (JNJ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Despite all the positivity, investors should think about adding a few large-cap stocks that pay a solid dividend to help anchor their portfolios in 2020...
Healthpeak's (PEAK) lease with Janssen BioPharma at The Shore at Sierra Point reflects solid demand for space at this centrally-located property in the large life-science cluster.
Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Glaxo (GSK) submits an MAA in Europe for its investigational candidate fostemsavir, which is being developed for treating HIV-1 infection in heavily pre-treated adult HIV patients.
The Zacks Analyst Blog Highlights: JPMorgan Chase, Johnson & Johnson, American Express Company, NIKE and Apple
There has been a particularly sharp run-up in blue-chip stocks. These companies are slated to see gains as they have strong balance sheet and solid cash flow.
Pacira's (PCRX) phase IV CHOICE study on its lead drug Exparel in patients undergoing Cesarean section attains the primary as well as key secondary endpoints.